Evotec AG Completes Acquisition of KINAXO Biotechnologies

Published: Apr 19, 2011

HAMBURG, Germany, April 19, 2011 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) today announced that it has completed the acquisition of Kinaxo Biotechnologies GmbH, a privately held drug discovery alliance company supporting the development of targeted drugs. As a result of the transaction, first announced on February 9, 2011, Kinaxo has become a wholly-owned subsidiary of Evotec. It is intended to grow and fully integrate the Kinaxo site in Munich, as Evotec Munich.

Back to news